Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
Background Raltegravir is the first integrase inhibitor to get into the clinic and the MK‐0518 Expanded Access Program (EAP) started in Italy in 2007, so that most patients now have [...]